Open AccessTreatment for systemic sclerosis-associated interstitial lung disease
Author(s) -
David Roofeh,
Alain Lescoat,
Dinesh Khanna
Publication year - 2021
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0000000000000795
Subject(s) - medicine , interstitial lung disease , nintedanib , tocilizumab , disease , scleroderma (fungus) , intensive care medicine , hematopoietic stem cell transplantation , clinical trial , oncology , lung , pathology , idiopathic pulmonary fibrosis , inoculation
This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios.